COMPOSITION FOR USE IN THE TREATMENT OF GLIOMA AND GLIOMA-INDUCED EPILEPSY

  • SISSA
  • From Italy
  • Responsive
  • Patents for licensing

Summary of the technology

Composition comprising R-Ketorolac, Bumetadine, at least one Cl channel blocker and Infliximab (intended for use in the treatment of glioma-associated epilepsy) which has an inhibitory effect on the infiltration of brain tumor cells and acts without blocking physiological neuronal signaling, ensuring a potential antiepileptic effect on neuronal circuits.

SISSA

Details of the Technology Offer

A new formulation has been developed to inhibit cancer cell proliferation, which blocks the increase in cell volume necessary for their replication, as well as a patented combination of FDA-approved compounds for the treatment of glioma and glioma-induced epilepsy. The composition has an almost negligible effect on the electrical activity of healthy neurons. In addition, infliximab reduces epileptic discharges induced in neurons by exosomes derived from glioma patients (of all grades). The formulation includes R-Ketorolac, Bumetadine, at least one Cl channel and Infliximab (intended for use in the treatment of glioma-associated epilepsy). The possible combinations of inhibitors (ion channels, membrane and cytoskeletal proteins) for specific cancer types are endless, and our team has decades of experience in modulating these targets. We are currently validating new drug combinations for breast and colorectal cancers.

POSSIBLE APPLICATIONS

  • Can be further developed into new lipophilic prodrugs formulations for blood-brain barrier penetration;
  • Bumetanide can be administered in the form of lipophilic prodrugs for CNS targeting;
  • Effectiveness in treating different neurological disorders, ie schizophrenia, autism, temporal lobe epilepsy.

ADVANTAGES

  • The formulation has:
    • (a) An inhibitory effect on the infiltration (invasiveness) of brain tumour cells while not blocking the physiological neuronal signalling;
    • (b) A potential antiepileptic effect on neuronal circuits, in particular when affected by tumour-released exosomes.

Intellectual property status

  • Patent already applied for
  • Patent application number :102021000022106

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Neurology, Brain Research
  • Medical Health related
  • Therapeutic
  • Anatomy, Pathology, Immunology, Physiology

About SISSA

Founded in 1978, SISSA Scuola Internazionale Superiore di Studi Avanzati of Trieste, Italy, is a leading institute for research and postgraduate training on the national and international stage. It is one of the six schools of excellence in Italy.
The aim of the School is to promote the development of scientific research and intellectual culture, all the while preparing young graduate students for advanced research, both pure and applied. The School was initially active in the so-called “hard sciences”, before expanding its range of activities to comprise new fields such as Neuroscience, Structural-Functional Genomics, Data Science and Science Communication. Research and training activities are grouped within three main areas: Physics, Mathematics and Neuroscience.
Besides its traditional pillars (Higher education and Research), in the recent years SISSA has been constantly working to promote new activities and initiatives focused on fostering the societal and economic development of the local Territory, the so called Third Mission to promote innovation and knowledge transfer.
For more information on SISSA innovation technologies and know-how, please contact us at valorisation@sissa.it

SISSA

Never miss an update from SISSA

Create your free account to connect with SISSA and thousands of other innovative organizations and professionals worldwide

SISSA

Send a request for information
to SISSA

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support